Engager T cells: A new class of antigen-specific t cells that redirect bystander T cells

Molecular Therapy

Volumn 23, Issue 1, 2015, Pages 171-178

  Iwahori, Kota ^a,b   Kakarla, Sunitha ^a,b   Velasquez, Mireya P ^a,b   Yu, Feng ^a   Yi, Zongzhen ^a,b   Gerken, Claudia ^a,b   Song, Xiao Tong ^a,b   Gottschalk, Stephen ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; EPHRIN RECEPTOR A2; TUMOR ANTIGEN;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; ENGAGER T CELL; EX VIVO STUDY; FLOW CYTOMETRY; GLIOBLASTOMA CELL LINE; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; K562 CELL LINE; LUNG CANCER; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SEVERE COMBINED IMMUNODEFICIENCY; T LYMPHOCYTE; TUMOR CELL; TUMOR XENOGRAFT; U373 CELL LINE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BRAIN NEOPLASMS; BYSTANDER EFFECT; CYTOLOGY; DRUG SCREENING; GENE EXPRESSION; GENE VECTOR; GENETICS; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; LUNG NEOPLASMS; MALE; MORTALITY; PATHOLOGY; PROCEDURES; RETROVIRIDAE; SCID MOUSE; SURVIVAL ANALYSIS; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD3; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; BYSTANDER EFFECT; CELL LINE, TUMOR; GENE EXPRESSION; GENETIC VECTORS; GLIOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED ICR; MICE, SCID; RECEPTOR, EPHA2; RETROVIRIDAE; SURVIVAL ANALYSIS; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920691639     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.156     Document Type: Article

References (46)

1. Morgan, RA, Dudley, ME and Rosenberg, SA (2010). Adoptive cell therapy: genetic modifcation to redirect effector cell specifcity. Cancer J 16: 336-341.
2. June, C, Rosenberg, SA, Sadelain, M and Weber, JS (2012). T-cell therapy at the threshold. Nat Biotechnol 30: 611-614.
3. Porter, DL, Levine, BL, Kalos, M, Bagg, A and June, CH (2011). Chimeric antigen receptor-modifed T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
4. Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR et al. (2013). Chimeric antigen receptor-modifed T cells for acute lymphoid leukemia. N Engl J Med 368: 1509-1518.
5. Kochenderfer, JN, Dudley, ME, Feldman, SA, Wilson, WH, Spaner, DE, Maric, I et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709-2720.
6. Brentjens, RJ, Davila, ML, Riviere, I, Park, J, Wang, X, Cowell, LG et al. (2013). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5: 177ra38.
7. Leen, AM, Rooney, CM and Foster, AE (2007). Improving T cell therapy for cancer. Annu Rev Immunol 25: 243-265.
8. Gajewski, TF, Meng, Y, Blank, C, Brown, I, Kacha, A, Kline, J et al. (2006). Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213: 131-145.
9. Rabinovich, GA, Gabrilovich, D and Sotomayor, EM (2007). Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296.
10. Riethmüller, G (2012). Symmetry breaking: bispecifc antibodies, the beginnings, and 50 years on. Cancer Immun 12: 12.
11. Weidle, UH, Tiefenthaler, G, Weiss, EH, Georges, G and Brinkmann, U (2013). The intriguing options of multispecifc antibody formats for treatment of cancer. Cancer Genomics Proteomics 10: 1-18.
12. Frankel, SR and Baeuerle, PA (2013). Targeting T cells to tumor cells using bispecifc antibodies. Curr Opin Chem Biol 17: 385-392.
13. Fournier, P and Schirrmacher, V (2013). Bispecifc antibodies and trispecifc immunocytokines for targeting the immune system against cancer: preparing for the future. BioDrugs 27: 35-53.
14. Bargou, R, Leo, E, Zugmaier, G, Klinger, M, Goebeler, M, Knop, S et al. (2008). Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321: 974-977.
15. Baeuerle, PA and Reinhardt, C (2009). Bispecifc T-cell engaging antibodies for cancer therapy. Cancer Res 69: 4941-4944.
16. Biao-xue, R, Xi-guang, C, Shuan-ying, Y, Wei, L and Zong-juan, M (2011). EphA2-dependent molecular targeting therapy for malignant tumors. Curr Cancer Drug Targets 11: 1082-1097.
17. Wykosky, J and Debinski, W (2008). The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 6: 1795-1806.
18. Chow, KK, Naik, S, Kakarla, S, Brawley, VS, Shaffer, DR, Yi, Z et al. (2013). T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther 21: 629-637.
19. Kakarla, S, Chow, KK, Mata, M, Shaffer, DR, Song, XT, Wu, MF et al. (2013). Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther 21: 1611-1620.
20. Kakarla, S, Chow, KK, Mata, M, Shaffer, DR, Song, XT, Wu, MF et al. (2013). Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther 21: 1611-1620.
21. Sadelain, M, Brentjens, R and Rivière, I (2013). The basic principles of chimeric antigen receptor design. Cancer Discov 3: 388-398.
22. Barber, A, Zhang, T and Sentman, CL (2008). Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J Immunol 180: 72-78.
23. Hunder, NN, Wallen, H, Cao, J, Hendricks, DW, Reilly, JZ, Rodmyre, R et al. (2008). Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358: 2698-2703.
24. Nagorsen, D, Kufer, P, Baeuerle, PA and Bargou, R (2012). Blinatumomab: a historical perspective. Pharmacol Ther 136: 334-342.
25. Klinger, M, Brandl, C, Zugmaier, G, Hijazi, Y, Bargou, RC, Topp, MS et al. (2012). Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecifc BiTE antibody blinatumomab. Blood 119: 6226-6233.
26. Kershaw, MH, Wang, G, Westwood, JA, Pachynski, RK, Tiffany, HL, Marincola, FM et al. (2002). Redirecting migration of T cells to chemokine secreted from tumors by genetic modifcation with CXCR2. Hum Gene Ther 13: 1971-1980.
27. Di Stasi, A, De Angelis, B, Rooney, CM, Zhang, L, Mahendravada, A, Foster, AE et al. (2009). T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113: 6392-6402.
28. Craddock, JA, Lu, A, Bear, A, Pule, M, Brenner, MK, Rooney, CM et al. (2010). Enhanced tumor traffcking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 33: 780-788.
29. Heslop, HE, Slobod, KS, Pule, MA, Hale, GA, Rousseau, A, Smith, CA et al. (2010). Long-term outcome of EBV-specifc T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115: 925-935.
30. Rosenberg, SA, Restifo, NP, Yang, JC, Morgan, RA and Dudley, ME (2008). Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308.
31. Maude, SL, Barrett, D, Teachey, DT and Grupp, SA (2014). Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 20: 119-122.
32. Suntharalingam, G, Perry, MR, Ward, S, Brett, SJ, Castello-Cortes, A, Brunner, MD et al. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018-1028.
33. Kolb, HJ (2008). Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112: 4371-4383.
34. Loskog, A, Giandomenico, V, Rossig, C, Pule, M, Dotti, G and Brenner, MK (2006). Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20: 1819-1828.
35. Stephan, MT, Ponomarev, V, Brentjens, RJ, Chang, AH, Dobrenkov, KV, Heller, G et al. (2007). T cell-encoded CD80 and 4-1BBL induce auto-and transcostimulation, resulting in potent tumor rejection. Nat Med 13: 1440-1449.
36. Carpenito, C, Milone, MC, Hassan, R, Simonet, JC, Lakhal, M, Suhoski, MM et al. (2009). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 106: 3360-3365.
37. Zhang, L, Kerkar, SP, Yu, Z, Zheng, Z, Yang, S, Restifo, NP et al. (2011). Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 19: 751-759.
38. Kerkar, S P, Leonardi, AJ, van Panhuys, N, Zhang, L, Yu, Z, Crompton, JG et al. (2013). Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther 21: 1369-1377.
39. Hoyos, V, Savoldo, B, Quintarelli, C, Mahendravada, A, Zhang, M, Vera, J et al. (2010). Engineering CD19-specifc T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24: 1160-1170.
40. Perna, SK, De Angelis, B, Pagliara, D, Hasan, ST, Zhang, L, Mahendravada, A et al. (2013). Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res 19: 106-117.
41. Arber, C, Abhyankar, H, Heslop, H, Dotti, G and Savoldo, B (2013). ab-T cell receptor-based gene therapy targeting the common tumor-antigen survivin for therapy of hematological malignancies. Mol Ther 21: S117.
42. Damschroder, MM, Widjaja, L, Gill, PS, Krasnoperov, V, Jiang, W, Dall'Acqua, WF et al. (2007). Framework shuffing of antibodies to reduce immunogenicity and manipulate functional and biophysical properties. Mol Immunol 44: 3049-3060.
43. Kufer, P, Lutterbuse, R, Kohlheisen, B, Zeman, S and Baeuerle, P (2007). Single chain antibody construct comprising binding domains specifc for human CD3 and human CD19; anticarcinogenic biodrug for treating non-Hodgkin lymphoma. Patent US20070123479.
44. Yu, F, Wang, X, Guo, ZS, Bartlett, DL, Gottschalk, SM and Song, XT (2014). T-cell engager-armed oncolytic vaccinia virus signifcantly enhances antitumor therapy. Mol Ther 22: 102-111.
45. Nicholson, IC, Lenton, KA, Little, DJ, Decorso, T, Lee, FT, Scott, AM et al. (1997). Construction and characterisation of a functional CD19 specifc single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol Immunol 34: 1157-1165.
46. Gottschalk, S, Edwards, OL, Sili, U, Huls, MH, Goltsova, T, Davis, AR et al. (2003). Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 101: 1905-1912.